Skip To Main Content
This platform is for Australian healthcare professionals only
Campus
Campus

Nexviazyme (avalglucosidase alfa) Mechanism of Action

Watch this video to learn how lacking or dysfunctional GAA impairs patients with Pompe disease and how enzyme replacement therapies, specifically NEXVIAZYME, work to reduce glycogen buildup within lysosomes.

Nexviazyme is not indicated for use in infants (<1 year of age). For infants, Myozyme may be an appropriate choice.


Nexviazyme has more mannose-6-phosphate (M6P) moieties than Myozyme (alglucosidase alfa)1

Nexviazyme is a recombinant human acid α-glucosidase (rhGAA) that provides an exogenous source of GAA. Nexviazyme has a 15-fold increase in M6P moieties compared with Myozyme. Increasing the level of M6P provides a mechanism to drive uptake into the diaphragm and other skeletal muscle via the cation-independent M6P receptor, where it can degrade glycogen and ameliorate tissue damage.1-3*

For illustrative purposes only.

View Nexviazyme Resources

*Pre-clinical and animal data may not necessarily predict clinical effect.

†Myozyme was the first ERT approved for the treatment of Pompe disease.4

Abbreviations

ERT, enzyme replacement therapy; GAA, acid α-glucosidase; M6P, mannose-6-phosphate.

References

  1. Nexviazyme Australian Approved Product Information.
  2. Zhu Y, et al. Mol Ther 2009;17(6):954-963.
  3. Zhu Y, et al. Biochem J 2005;389:619-628.
  4. van der Ploeg AT, et al. N Engl J Med 2010;362(15):1396-1406.

PBS Information: NEXVIAZYME. This product is not listed on the PBS. This product is funded under the Life Saving Drugs Program.

Please review full Nexviazyme Product Information before prescribing. Full Product Information is available from sanofi-aventis australia pty ltd here or by contacting 1800 818 806.

â–¼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

 

PBS Information: MYOZYME. This product is not listed on the PBS. This product is funded under the Life Saving Drugs Program.

Please review full Myozyme Product Information before prescribing. Full Product Information is available from sanofi-aventis australia pty ltd here or by contacting 1800 818 806.

Life Saving Drugs Program - Pompe disease - Guidelines are available at www.health.gov.au/resources/publications/lsdp-pompe-guidelines.

Nexviazyme® and Myozyme​​​​​​​® are registered trademarks of Sanofi.

MAT-AU-2201158-2.0 - 05/2024.